Filter posts

Patent Reform Needs to Address Trolling of All Stripes

As we enter the final days of the 114th Congress, it is regrettable that the …

PTAB, IPRs and Uncertainty in the Patent System

The topic of inter partes reviews (IPRs) has dominated conversation in patent circles for the …

Will the PTAB Be A Roadblock for Biotech? Stories from Sessions at BIO 2016

We’re at the beginning of day 3 here at BIO 2016, and that means we’ve already had …

"II Ca-Be-lly, or Not II Ca-Be-lly?”: Is The Famous Cabilly II Antibody Patent Near Extinction?

Guest post by Konstantin Linnik, Ph.D., Isaac Hubner, Ph.D, and Lana Gladstein, who are attorneys …

Patent Reform in the News

The New York Post and The Washington Post have both run Op-eds in the last week addressing …

225th Anniversary of First U.S. Patent

225 years ago last Friday the first U.S. patent was issued to Samuel Hopkins for …

IP Sessions at BIO 2015: The Impact of the Inter Partes Review on (BIO)Pharma

The Intellectual Property Track at the BIO International Convention was a chance for IP thought …

Sen Menendez Asks SEC to Investigate IPR Abuses

New Jersey Senator Bob Menendez has asked the Securities and Exchange Commissioner (SEC) to investigate …

IP Sessions at the 2015 BIO International Convention

This year’s BIO International Convention will be host to educational sessions on the latest issues …

BIO Deputy General Counsel Testifies on Patent Reform

On Wednesday, March 18, BIO’s Deputy Counsel for Intellectual Property, Hans Sauer, testified in front …